JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colnot, D. R.
Right arrow Articles by van Dongen, G. A.M.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colnot, D. R.
Right arrow Articles by van Dongen, G. A.M.S.

Evaluation of Limited Blood Sampling in a Preceding 99mTc-Labeled Diagnostic Study to Predict the Pharmacokinetics and Myelotoxicity of 186Re-cMAb U36 Radioimmunotherapy

David R. Colnot, Abraham J. Wilhelm, Jacqueline Cloos, Jan C. Roos, Remco de Bree, Jasper J. Quak, Gordon B. Snow and Guus A.M.S. van Dongen

Departments of Otolaryngology/Head and Neck Surgery and Nuclear Medicine, Vrije Universiteit Medical Center, Amsterdam, The Netherlands



View larger version (17K):

[in a new window]
  		FIGURE 1. Relationship between red marrow absorbed dose estimates and development of thrombocytopenia after 186Re-cMAb U36 radioimmunotherapy. Red marrow absorbed dose estimate was calculated using Bayesian analysis of limited blood sampling at 4 and 72 h after administration of 186Re-cMAb U36.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.